An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors
Phase 1
Recruiting
- Conditions
- on-Small Cell Lung Cancer, cutaneous melanoma, urothelial cancer,renal cell cancer, Squamous Cell Carcinoma of the Head and NeckTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-513716-95-00
- Lead Sponsor
- ec Oncoimmunity AS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method